Show simple item record

dc.contributor.authorHead, Michael G.en_US
dc.contributor.authorFitchett, Joseph R.en_US
dc.contributor.authorCooke, Mary K.en_US
dc.contributor.authorWurie, Fatima B.en_US
dc.contributor.authorAtun, Rifaten_US
dc.contributor.authorHayward, Andrew C.en_US
dc.contributor.authorHolmes, Alisonen_US
dc.contributor.authorJohnson, Alan P.en_US
dc.contributor.authorWoodford, Neilen_US
dc.date.accessioned2014-03-11T13:25:40Z
dc.date.issued2013en_US
dc.identifier.citationHead, Michael G., Joseph R. Fitchett, Mary K. Cooke, Fatima B. Wurie, Rifat Atun, Andrew C. Hayward, Alison Holmes, Alan P. Johnson, and Neil Woodford. 2013. “Systematic analysis of funding awarded for antimicrobial resistance research to institutions in the UK, 1997–2010.” Journal of Antimicrobial Chemotherapy 69 (2): 548-554. doi:10.1093/jac/dkt349. http://dx.doi.org/10.1093/jac/dkt349.en
dc.identifier.issn0305-7453en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:11879523
dc.description.abstractObjectives: To assess the level of research funding awarded to UK institutions specifically for antimicrobial resistance-related research and how closely the topics funded relate to the clinical and public health burden of resistance. Methods: Databases and web sites were systematically searched for information on how infectious disease research studies were funded for the period 1997–2010. Studies specifically related to antimicrobial resistance, including bacteriology, virology, mycology and parasitology research, were identified and categorized in terms of funding by pathogen and disease and by a research and development value chain describing the type of science. Results: The overall dataset included 6165 studies receiving a total investment of £2.6 billion, of which £102 million was directed towards antimicrobial resistance research (5.5% of total studies, 3.9% of total spend). Of 337 resistance-related projects, 175 studies focused on bacteriology (40.2% of total resistance-related spending), 42 focused on antiviral resistance (17.2% of funding) and 51 focused on parasitology (27.4% of funding). Mean annual funding ranged from £1.9 million in 1997 to £22.1 million in 2009. Conclusions: Despite the fact that the emergence of antimicrobial resistance threatens our future ability to treat many infections, the proportion of the UK infection-research spend targeting this important area is small. There are encouraging signs of increased investment in this area, but it is important that this is sustained and targeted at areas of projected greatest burden. Two areas of particular concern requiring more investment are tuberculosis and multidrug-resistant Gram-negative bacteria.en
dc.language.isoen_USen
dc.publisherOxford University Pressen
dc.relation.isversionofdoi:10.1093/jac/dkt349en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886928/pdf/en
dash.licenseLAAen_US
dc.subjectantibioticsen
dc.subjectantifungalen
dc.subjectantiviralen
dc.subjectantiparasiticen
dc.titleSystematic analysis of funding awarded for antimicrobial resistance research to institutions in the UK, 1997–2010en
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalJournal of Antimicrobial Chemotherapyen
dash.depositing.authorAtun, Rifaten_US
dc.date.available2014-03-11T13:25:40Z
dc.identifier.doi10.1093/jac/dkt349*
dash.contributor.affiliatedAtun, Rifat
dc.identifier.orcid0000-0002-1531-5983


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record